Breast Diseases  >>  epirubicin  >>  Phase 3
Welcome,         Profile    Billing    Logout  

46 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
epirubicin / Generic mfg.
NCT00002870: High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Locally Recurrent or Metastatic Breast Cancer

Completed
3
180
Europe
filgrastim, cyclophosphamide, epirubicin hydrochloride, fluorouracil, thiotepa, peripheral blood stem cell transplantation
UNICANCER
Breast Cancer
01/02
01/02
NCT00002544: Mitoxantrone With or Without Docetaxel in Treating Women With Metastatic Breast Cancer

Completed
3
300
Europe
docetaxel, mitoxantrone hydrochloride
Arbeitsgemeinschaft fur Internistische Onkologie
Breast Cancer
 
11/02
NCT00053911: Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer

Terminated
3
Europe
anastrozole, cyclophosphamide, docetaxel, epirubicin hydrochloride, fluorouracil, goserelin acetate, tamoxifen citrate, adjuvant therapy
UNICANCER
Breast Cancer
04/04
 
NCT00038402: Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

Completed
3
74
US
Herceptin, Trastuzumab, Taxol, Paclitaxel, Fluorouracil, Cytoxan, Cyclophosphamide, Neosar, Epirubicin
M.D. Anderson Cancer Center, Genentech, Inc.
Breast Cancer
11/04
07/11
NCT00668616: Adjuvant Treatment of Breast Cancer With 1-3 Aflicted Lymph Nodes

Completed
3
1034
Europe
Cyclophosphamide, Epirubicin, Paclitaxel, Epirubicin, Paclitaxel, Filgrastim
North Eastern German Society of Gynaecological Oncology
Breast Cancer
07/05
07/09
NCT00002953: Epirubicin and Cyclophosphamide Compared With Epirubicin and Paclitaxel in Treating Women With Metastatic Breast Cancer

Completed
3
704
Europe, RoW
cyclophosphamide, epirubicin hydrochloride, paclitaxel
Medical Research Council
Breast Cancer
 
11/05
NCT00003893: Adjuvant Chemotherapy Plus Radiation Therapy in Treating Women With Early-Stage Breast Cancer

Completed
3
2250
Europe
CMF regimen, cyclophosphamide, doxorubicin hydrochloride, epirubicin hydrochloride, fluorouracil, methotrexate, mitomycin C, mitoxantrone hydrochloride, adjuvant therapy, radiation therapy
University Hospital Birmingham
Breast Cancer
 
04/06
TEX trial, NCT01433614: Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer

Checkmark
Jun 2013 - Jun 2013: 
Completed
3
304
Europe
Epirubicin, Paclitaxel, Taxol, Capecitabine, Xeloda
Thomas Hatschek
Metastatic Breast Cancer
06/06
12/13
NCT00140075: Adjuvant Epirubicin/Cytoxan Followed By A Taxane VS. Epirubicin/Taxane As Treatment For Node-Positive Breast Cancer

Completed
3
606
US
Epirubicin with Cyclophosphamide, followed by a Taxane, Epirubicin, ellence,, Epirubicin with a Taxane
Pfizer
Adenocarcinoma
08/06
08/06
PREPARE, NCT00544232: Preoperative Epirubicin Paclitaxel Aranesp Study

Completed
3
720
Europe
Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa, Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa
German Breast Group, Pharmacia, Amgen, Bristol-Myers Squibb
Breast Cancer
09/06
09/06
SAKK-EORTC-10994, NCT00017095: Biomarker (p53 Gene) Analysis and Combination Chemotherapy Followed by Radiation Therapy and Surgery in Treating Women With Large Operable or Locally Advanced or Inflammatory Breast Cancer

Checkmark EBCC 2014
Mar 2014 - Mar 2014: EBCC 2014
Checkmark
Mar 2013 - Mar 2013: 
Completed
3
1856
Europe
filgrastim, cyclophosphamide, docetaxel, epirubicin hydrochloride, fluorouracil, microarray analysis, immunohistochemistry staining method, laboratory biomarker analysis, biopsy, conventional surgery, neoadjuvant therapy, radiation therapy
European Organisation for Research and Treatment of Cancer - EORTC, Swedish Breast Cancer Group, Swiss Group for Clinical Cancer Research, Anglo Celtic Cooperative Oncology Group
Breast Cancer
11/06
 
PERCHE, NCT00066807 / 2005-002626-59: Premenopausal Endocrine Responsive Chemotherapy Trial

Terminated
3
29
Europe
chemotherapy, Ellence, Epirubicin Ebewe, exemestane, Aromasin, tamoxifen, Nolvadex, triptorelin, GnRH analog, Trelstar Depot, oophorectomy, ovarian irradiation
ETOP IBCSG Partners Foundation, National Cancer Institute (NCI), Breast International Group
Breast Cancer
12/06
12/06
NCT00336791: Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer

Completed
3
273
US, Europe, RoW
5-Fluorouracil, 5-FU, Adrucil, Efudex, Cyclophosphamide, Cytoxan, Neosar, Doxorubicin, AD, Hydroxydaunomycin hydrochloride, Paclitaxel, Taxol, Epirubicin
M.D. Anderson Cancer Center, Breast Cancer Research Foundation
Breast Cancer
08/07
09/10
NCT00429871: Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer

Completed
3
272
Europe
Docetaxel, Taxotere, Capecitabine, Xeloda, Epirubicin, Farmorubicin
Hellenic Oncology Research Group, University Hospital of Crete
Breast Cancer
11/07
11/07
PROMISE-GIM6, NCT00311636: Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery

Completed
3
280
Europe
cyclophosphamide, docetaxel, doxorubicin hydrochloride, epirubicin hydrochloride, fluorouracil, methotrexate, paclitaxel, triptorelin, adjuvant therapy
Gruppo Italiano Mammella (GIM)
Breast Cancer
01/08
04/08
NCT00003577: Combination Chemotherapy With or Without Epirubicin in Treating Women With Stage I or Stage II Breast Cancer

Completed
3
2000
Europe
CMF regimen, cyclophosphamide, epirubicin hydrochloride, fluorouracil, methotrexate, adjuvant therapy, radiation therapy
University Hospital Birmingham
Breast Cancer
 
09/08
PACS04, NCT00054587: Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

Checkmark Biomarker data
Jun 2013 - Jun 2013: Biomarker data
Completed
3
3010
Europe
Trastuzumab, Herceptin, Cyclophosphamide, docetaxel, Epirubicin, epirubicin hydrochloride, Fluorouracil
UNICANCER
Breast Cancer
06/09
12/09
BREAST-10, NCT00540800: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer

Completed
3
139
Europe
docetaxel, epirubicin, capecitabine
National Cancer Institute, Naples
Breast Cancer
09/09
12/09
NCT00309556 / 2004-002030-19: Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer

Checkmark Epirubicin & docetaxel with or without capecitabine as neoadj treatment for early BC
Dec 2013 - Dec 2013:  Epirubicin & docetaxel with or without capecitabine as neoadj treatment for early BC
Completed
3
536
Europe
Epirubicin, Docetaxel, Taxotere, Capecitabine, Xeloda, Trastuzumab, Herceptin
Austrian Breast & Colorectal Cancer Study Group, Amgen, Ebewe Pharma GmbH, Hoffmann-La Roche, Sanofi
Breast Cancer
11/09
11/11
NCT00963729 / 2006-003596-12: Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery

Completed
3
756
Europe, RoW
cyclophosphamide, docetaxel, epirubicin hydrochloride, fluorouracil, letrozole
Imperial College London
Breast Cancer
03/10
03/11
EU-93015, NCT00002529: Hormone Therapy and Chemotherapy in Treating Perimenopausal or Postmenopausal Women With Node-Positive Breast Cancer

Completed
3
452
Europe, RoW
cyclophosphamide, doxorubicin hydrochloride, epirubicin hydrochloride, tamoxifen citrate, toremifene
ETOP IBCSG Partners Foundation
Breast Cancer
08/10
08/10
BO22227, NCT00950300 / 2008-007326-19: A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

Checkmark P3 data - ESMO
Sep 2012 - Sep 2012: P3 data - ESMO
Checkmark P3 data - ESMO
Sep 2012 - Sep 2012: P3 data - ESMO
Checkmark P3 data - ESMO
More
Completed
3
596
Canada, Europe, RoW
5-Fluorouracil, Cyclophosphamide, Docetaxel, Epirubicin, Herceptin IV [trastuzumab], Herceptin SC [trastuzumab]
Hoffmann-La Roche
Breast Cancer
07/11
01/17
IBCSG-15-95, NCT00002784: High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast Cancer

Completed
3
344
Europe, RoW
filgrastim, CMF regimen, cyclophosphamide, doxorubicin hydrochloride, epirubicin hydrochloride, fluorouracil, mesna, methotrexate, tamoxifen citrate, peripheral blood stem cell transplantation, low-LET electron therapy, low-LET photon therapy
ETOP IBCSG Partners Foundation
Breast Cancer
08/11
12/11
GeparQuinto, NCT00567554 / 2006-005834-19: Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer

Checkmark SABCS 2014
Dec 2014 - Dec 2014: SABCS 2014
Checkmark In HER2-positive breast cancer pts
Aug 2014 - Aug 2014: In HER2-positive breast cancer pts
Checkmark Results from the GeparQuinto study (GBG 44)
More
Completed
3
2600
Europe
epirubicin - cyclophosphamide / docetaxel, epirubicin - cyclophosphamide / docetaxel + bevacizumab, paclitaxel, paclitaxel + everolimus (RAD001), epirubicin - cyclophosphamide / docetaxel + trastuzumab, epirubicin - cyclophosphamide / docetaxel + lapatinib
German Breast Group, AGO Study Group
Breast Cancer
08/11
10/15
NCT00670878: Studying the Benefits of Adjuvant Sequential vs. Combined Taxane Based Chemotherapy, Followed by Different Biological Treatment Strategies in Early, HER2-positive Breast Cancer

Completed
3
799
Europe
3 x FEC 3 x DOC / Gemcitabine, 3 x FEC 3 x DOC
Ludwig-Maximilians - University of Munich
Breast Cancer
10/11
 
NCT00047099: Combination Chemotherapy in Treating Women With Breast Cancer

Checkmark Data-SABCS
Jan 2012 - Jan 2012: Data-SABCS
Checkmark Data
Aug 2011 - Aug 2011: Data
Checkmark Data
More
Completed
3
446
Europe
cyclophosphamide, docetaxel, epirubicin hydrochloride, fluorouracil, goserelin acetate, tamoxifen citrate, adjuvant therapy, radiation therapy
Ludwig-Maximilians - University of Munich
Breast Cancer
02/12
03/12
MIG5, NCT02450058: Adjuvant FEC Versus EP in Breast Cancer

Completed
3
1055
Europe
5-fluorouracil, epirubicin, cyclophosphamide, paclitaxel
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Breast Cancer, Chemotherapy, Adjuvant
05/12
05/12
NCT00615602: Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer

Checkmark ASCO 2014
May 2014 - May 2014: ASCO 2014
Completed
3
489
Europe
Docetaxel, Taxotere, Trastuzumab, Herceptin, Epirubicin, Farmorubicin, Cyclophosphamide, Endoxan, 5-fluoruracil, 5-FU, Granulocyte-colony stimulating growth factor, Granocyte, Neulasta
Hellenic Oncology Research Group, University Hospital of Crete
Breast Cancer
05/12
05/12
NATT, NCT00912444: Neoadjuvant Treatment of Docetaxel, Anthracycline and Cyclophosphamide (TAC) Versus Docetaxel and Cyclophosphamide (TC) in Triple-Negative or Her2 Positive Breast Cancer

Terminated
3
102
RoW
Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide, Docetaxel, cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Breast Cancer
05/12
10/15
NCT00055679: Combination Chemotherapy in Treating Women With Stage I Breast Cancer

Completed
3
1512
Europe
cyclophosphamide, epirubicin hydrochloride, fluorouracil
UNICANCER
Breast Cancer
06/12
06/13
NCT00513292: Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery

Checkmark Neoadjuvant treatment for pts with HER-2+ve BC
Nov 2013 - Nov 2013: Neoadjuvant treatment for pts with HER-2+ve BC
Checkmark ASCO 2013
May 2013 - May 2013: ASCO 2013
Checkmark ASCO-2013
More
Completed
3
280
US
Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Epirubicin Hydrochloride, Ellence, IMI-28, Pharmorubicin PFS, Laboratory Biomarker Analysis, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Therapeutic Conventional Surgery, Trastuzumab, ABP 980, Anti-c-ERB-2, Anti-c-erbB2 Monoclonal Antibody, Anti-ERB-2, Anti-erbB-2, Anti-erbB2 Monoclonal Antibody, Anti-HER2/c-erbB2 Monoclonal Antibody, Anti-p185-HER2, c-erb-2 Monoclonal Antibody, HER2 Monoclonal Antibody, Herceptin, Herceptin Biosimilar PF-05280014, Herceptin Trastuzumab Biosimilar PF-05280014, MoAb HER2, Monoclonal Antibody c-erb-2, Monoclonal Antibody HER2, PF-05280014, rhuMAb HER2, Trastuzumab Biosimilar ABP 980, Trastuzumab Biosimilar PF-05280014
National Cancer Institute (NCI)
HER2/Neu Positive, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
06/12
02/13
READ, NCT00689156 / 2007-003126-15: Epirubicin or Not in Patients With TOP2A (Topoisomerase (DNA) II Alpha (170kD)) Normal Early Breast Cancer

Completed
3
2015
Europe
Epirubicin, cyclophosphamide and docetaxel, Ellence, Taxotere, docetaxel, cyclophosphamide
Danish Breast Cancer Cooperative Group, Fonden Til Fremme af Klinisk- Eksperimentel Cancerforskning, Sanofi, Dako
Breast Neoplasms
01/13
01/13
NCT01611051: A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy

Completed
3
330
RoW
Drug: Pegylated rhG-CSF: 100µg/kg, Pegylated rhG-CSF: 6mg, rhG-CSF 5ug/kg/day
Jiangsu HengRui Medicine Co., Ltd.
Breast Cancer, Neutropenia, Febrile Neutropenia
01/13
 
NCT00424606: Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients

Completed
3
658
Europe
Docetaxel, Taxotere, Epirubicin, Farmorubicin
Hellenic Oncology Research Group, University Hospital of Crete
Breast Cancer
08/13
08/13
GeparQuattro, NCT00288002 / 2005-001546-17: Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Checkmark Neoadjuvant treatment of primary BC
Jan 2014 - Jan 2014: Neoadjuvant treatment of primary BC
Checkmark Primary breast cancer
Nov 2013 - Nov 2013: Primary breast cancer
Checkmark P3 biomarker data - ASCO
More
Completed
3
1500
Europe
trastuzumab, capecitabine, cyclophosphamide, docetaxel, epirubicin hydrochloride, adjuvant therapy, conventional surgery, neoadjuvant therapy
German Breast Group
Breast Cancer
 
 
NCT00003012: Combination Chemotherapy Following Surgery in Treating Women With Early Stage Breast Cancer

Completed
3
1000
Europe
CMF regimen, cyclophosphamide, epirubicin hydrochloride, fluorouracil, methotrexate
Scottish Cancer Therapy Network
Breast Cancer
 
 
NCT01985724: Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer

Completed
3
650
Europe
Docetaxel, Taxotere, Epirubicin, Farmorubicin, Cyclophosphamide, Endoxan, 5-fluoruracil, 5-FU, Granulocyte-colony stimulating growth factor, Granocyte, Neulasta
Hellenic Oncology Research Group, University Hospital of Crete
Breast Cancer
12/13
12/13
SOLD, NCT00593697 / 2007-002016-26: The Synergism Or Long Duration () Study

Completed
3
2168
Europe
trastuzumab (9 weeks) + docetaxel, trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)
Finnish Breast Cancer Group
Breast Neoplasms
11/14
11/14
IBCSG 22-00, NCT00022516: Low-dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-negative Early Breast Cancer

Completed
3
1086
Europe, RoW
Cyclophosphamide, Endoxan, Cytoxan, Methotrexate, Trexall
ETOP IBCSG Partners Foundation
Breast Cancer
01/15
08/16
Neo-shorter, NCT02001506: Neoadjuvant Chemotherapy of 6 Cycles vs 8 Cycles in Node Positve Breast Cancer

Completed
3
250
RoW
FEC3-D3, 5-FU, Pharmorubicin, Cytoxan, Docetaxel
Asan Medical Center
Breast Cancer
12/15
12/15
GeparOcto, NCT02125344 / 2014-000619-14: A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer

Completed
3
961
Europe
non-pegylated liposomal doxorubicin, Myocet, Carboplatin, Carbomedac, Paclitaxel, var., Epirubicin, Farmorubicin, Cyclophosphamide, Endoxan, Pertuzumab, Perjeta, Trastuzumab, Herceptin, Ferric carboxymaltose, Ferinject
German Breast Group, Amgen, Roche Pharma AG, Teva Pharmaceuticals USA, Vifor Pharma
Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS, Invasive Ductal Breast Cancer, HER2 Positive Breast Cancer, Inflammatory Breast Cancer
11/16
01/17
NCT02980965: Neoadjuvant Chemo-endocrine Therapy Versus Chemotherapy Alone in ER-positive, HER2-negative Breast Cancer

Completed
3
249
RoW
letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel, GnRH-a, ENANTONE, fluorouracil, epirubicin, cyclophosphamide, docetaxel
Fudan University
Breast Cancer Female
02/17
02/17
PERS, NCT03006614: Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer

Recruiting
3
320
RoW
NVB, vinorelbine, EPI, epirubicin, DDP, cisplatin, CAP, capecitabine, GEM, gemcitabine, H, Trastuzumab, CTX, cyclophosphamidem, T, docetaxel
Shi Yanxia
Breast Cancer Model, Effects of Chemotherapy, Breast Cancer
03/18
03/23
TACT2, NCT00301925: Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery

Active, not recruiting
3
4400
Europe
pegfilgrastim, capecitabine, cyclophosphamide, epirubicin hydrochloride, fluorouracil, methotrexate, adjuvant therapy
Institute of Cancer Research, United Kingdom
Breast Cancer
09/24
09/24
NCT01433562: Efficacy and Safety of DLBS1425 as Neoadjuvant in Stage II or III Breast Cancer Patients

Completed
2/3
40
RoW
DLBS1425, Placebo DLBS1425
Dexa Medica Group
Breast Cancer
11/12
11/12
NCT01204437 / 2008-003995-23: Adjuvant Chemotherapy for Elderly Non Frail Patients With an Increased Risk for Relapse of a Primary Carcinoma of the Breast

Checkmark EBCC 2014
Mar 2014 - Mar 2014: EBCC 2014
Completed
2/3
400
Europe
Epirubicin, Cyclophosphamide, Cyclophosphamide, Methotrexate, 5 FU, Capecitabine, Nab-Paclitaxel
German Breast Group
Breast Cancer
01/14
01/14

Download Options